ResearcherNew York UniversityActive in the last 2 years
Lawrence Leichman
Matched on OpenAlex author ID A5110213859, A5112829655. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 18
2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper
Papers 4
- Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study. Co-author DOI 10.1093/oncolo/oyaf271↗
- Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations. Co-author DOI 10.5306/wjco.v8.i3.230↗
- A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic … Last author DOI 10.1007/s00280-016-2981-2↗
- A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreate… Co-author DOI 10.1093/annonc/mdv477↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Colin D. Weekes · 2 shared papers, 2016–2025 · strength 0.28
- Paper Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal … DOI 10.1093/oncolo/oyaf271↗
- Paper A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated … DOI 10.1007/s00280-016-2981-2↗
- Deirdre Jill Cohen · 2 shared papers, 2015–2025 · strength 0.26
- Paper Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal … DOI 10.1093/oncolo/oyaf271↗
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv477↗
- Aaron James Scott · 2 shared papers, 2015–2025 · strength 0.26
- Paper Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal … DOI 10.1093/oncolo/oyaf271↗
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv477↗
- Wells A. Messersmith · 2 shared papers, 2015–2025 · strength 0.26
- Paper Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal … DOI 10.1093/oncolo/oyaf271↗
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv477↗
- Elliot Newman · 1 shared paper, 2025 · strength 0.22
- Tanios Bekaii‐Saab · 1 shared paper, 2025 · strength 0.22
- Alec J. Megibow · 1 shared paper, 2025 · strength 0.22
- Paul E. Oberstein · 1 shared paper, 2025 · strength 0.22
- Bert H. O’Neil · 2 shared papers, 2015–2016 · strength 0.09
- Paper A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated … DOI 10.1007/s00280-016-2981-2↗
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv477↗
- Jordan D. Berlin · 2 shared papers, 2015–2016 · strength 0.09
- Paper A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated … DOI 10.1007/s00280-016-2981-2↗
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv477↗
- Steven J. Cohen · 2 shared papers, 2015–2016 · strength 0.09
- Paper A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated … DOI 10.1007/s00280-016-2981-2↗
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv477↗
- Songchuan Guo · 1 shared paper, 2017 · strength 0.09
- Jennifer J. Wu · 1 shared paper, 2017 · strength 0.09
- George Miller · 1 shared paper, 2017 · strength 0.09
- Antonio Jimeno · 1 shared paper, 2015 · strength 0.03
- Mike Cusnir · 1 shared paper, 2015 · strength 0.03
- Olugbenga Olanrele Olowokure · 1 shared paper, 2015 · strength 0.03
- Autumn J. McRee · 1 shared paper, 2015 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.